Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
51.18 USD | -1.08% | -3.10% | -18.49% |
Apr. 24 | Oppenheimer Adjusts Incyte Price Target to $84 From $92, Maintains Outperform Rating | MT |
Apr. 23 | Transcript : Escient Pharmaceuticals, Inc., Incyte Corporation - M&A Call |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-18.49% | 11.49B | |
-4.66% | 87.53B | |
+2.63% | 40.42B | |
-21.76% | 29.48B | |
+58.56% | 25.43B | |
-14.78% | 15.59B | |
-15.61% | 11.1B | |
-44.02% | 11.3B | |
+5.17% | 8.75B | |
-7.95% | 7.99B |
- Stock Market
- Equities
- INCY Stock
- News Incyte Corporation
- Incyte : Fourth-Quarter Earnings Handily Beat Street Estimates on Strong Sales of Cancer Drug Jakafi